Interferon-a-2a (Roferon-A) is approved for the treatment of chronic hepatitis C, hairy cell leukemia, AIDS-related Kaposi's sarcoma, and chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia. Interferon-a-2b (Intron A) is indicated for hairy cell leukemia, malignant melanoma, follicular lymphoma, condylomata acuminata, AIDS-related Kaposi's sarcoma, and chronic hepatitis B and C. A combination of interferon-a-2b and ribavirin (Rebetron) is used for the treatment of chronic hepatitis C. Interferon-a-n3 (Alferon N) is a solution of purified natural human interferon-aproteins approved for the treatment of condy-lomata acuminata by intralesional injection. Interferon alfacon-1 (Infergen) is a recombinant interferon constructed from the sequences of several naturally occurring interferon-asubtypes. This recombinant protein contains the most frequently observed amino acid in each position of the sequence and exhibits in vitro specific activity at least 5 times higher than that of interferon a-2a or -2b. Interferon alfacon-1 and peg inter-feron-a-2b (PEG-Intron) are approved for the treatment of chronic hepatitis C.
Interferon (3-1a (Avonex) and interferon (3-1b (Betaseron) are used in the treatment of multiple sclerosis. Interferon ^-1b (Actimmune) is used to prevent and diminish the severity of infections associated with chronic granulomatous disease and for delaying the progression of severe, malignant osteopetrosis.
Was this article helpful?